Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.804 USD | -0.34% | +0.92% | -45.72% |
May. 21 | Palisade Bio, Inc. Announces Presentation of Positive Preclinical Data from PALI-2108 | CI |
May. 13 | Palisade Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.72% | 4.51M | |
+45.08% | 54.63B | |
-4.51% | 39.92B | |
+37.26% | 38.82B | |
+16.40% | 26.86B | |
-12.56% | 26.22B | |
-21.12% | 18.78B | |
+27.08% | 12.21B | |
+0.89% | 12.16B | |
+27.55% | 11.94B |
- Stock Market
- Equities
- SNCA Stock
- News Palisade Bio, Inc.
- Ladenburg Thalmann Adjusts Price Target on Palisade Bio to $16 From $25, Maintains Buy Rating